GlassScriptPhysician profile
Sue A Karnitis
NPI 1275535163
$201.22
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $147 · 2021: $53.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.66 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.93 | 2020 | |
| Kaleo, INC. | $37.23 | 2020-2021 | |
| Neos Therapeutics, LP | $31.89 | 2020 | |
| Genentech USA, INC. | $23.15 | 2020 | |
| Glaxosmithkline, LLC. | $12.07 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Karnitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.